Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"Roche, Consumer",Pertuzumab (IV form),"Breast cancer, HER2-positive, locally advanced, inflammatory or early-stage, neoadjuvant treatment",Pertuzumab (IV form),Options for investment,,Oncology Agents and Immunosuppressants
